福泰制药终止一肝病基因治疗合作！

谈思生物2025-03-02

02025.03.02本文字数：713，阅读时长大约2分钟导读：Vertex制药与Verve Therapeutics终止了为期四年的基因治疗合作，合作原计划开发针对肝脏疾病的基因编辑疗法。此次终止凸显了基因治疗领域的高风险性。与此同时，Verve的核心产品VERVE-102正在进行Ib期临床试验，预计2025年第二季度公布初步数据。此外，Verve与Eli Lilly的合作进展也将成为未来的关键...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2516422519?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-02 19:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2516422519","market":"us","top_or_hot":-1,"title":"福泰制药终止一肝病基因治疗合作！","media":"谈思生物","content":"<div>\n<p>02025.03.02本文字数：713，阅读时长大约2分钟导读：Vertex制药与Verve Therapeutics终止了为期四年的基因治疗合作，合作原计划开发针对肝脏疾病的基因编辑疗法。此次终止凸显了基因治疗领域的高风险性。与此同时，Verve的核心产品VERVE-102正在进行Ib期临床试验，预计2025年第二季度公布初步数据。此外，Verve与Eli Lilly的合作进展也将成为未来的关键...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302191833abe4671f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>福泰制药终止一肝病基因治疗合作！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n福泰制药终止一肝病基因治疗合作！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-02 19:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302191833abe4671f&s=b><strong>谈思生物</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>02025.03.02本文字数：713，阅读时长大约2分钟导读：Vertex制药与Verve Therapeutics终止了为期四年的基因治疗合作，合作原计划开发针对肝脏疾病的基因编辑疗法。此次终止凸显了基因治疗领域的高风险性。与此同时，Verve的核心产品VERVE-102正在进行Ib期临床试验，预计2025年第二季度公布初步数据。此外，Verve与Eli Lilly的合作进展也将成为未来的关键...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302191833abe4671f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3B42.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302191833abe4671f&s=b","article_id":"2516422519","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302191833abe4671f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2516422519","pubTimestamp":1740913309,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"02025.03.02本文字数：713，阅读时长大约2分钟导读：Vertex制药与Verve Therapeutics终止了为期四年的基因治疗合作，合作原计划开发针对肝脏疾病的基因编辑疗法。此次终止凸显了基因治疗领域的高风险性。近日，Vertex Pharmaceuticals和Verve Therapeutics联合宣布，终止一项持续了四年的基因治疗合作。值得注意的是，Verve的主要候选药物VERVE-102正是一款针对肝脏的基因编辑疗法。这种遗传性疾病会增加患者中风和心脏病发作的风险。尽管Verve与Vertex的合作告一段落，但这并未阻碍其与其他大型制药企业的合作。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4139":"生物科技","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","VRTX":"福泰制药","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","BK4567":"ESG概念","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4585":"ETF&股票定投概念","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC"},"translate_title":"Futai Pharmaceutical terminates a liver disease gene therapy cooperation!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"02025.03.02本文字数：713，阅读时长大约2分钟导读：Vertex制药与Verve Therapeutics终止了为期四年的基因治疗合作，合作原计划开发针对肝脏疾病的基因编辑疗法。此次终止凸显了基因治疗领域的高风险性。与此同时，Verve的核心产品VERVE-102正在进行Ib期临床试验，预计2025年第二季度公布初步数据。此外，Verve与Eli Lilly的合作进展也将成为未来的关键观察点。近日，Vertex Pharmaceuticals（以下简称“Vertex”）和Verve Therapeutics（以下简称“Verve”）联合宣布，终止一项持续了四年的基因治疗合作。该合作最初于2022年启动，总价值达4亿美元，其中包括6000万美元的预付款以及后续研发和商业化里程碑付款等相关款项。双方原本计划共同开发基于体内基因编辑技术的肝脏疾病基因疗法。据了解，Vertex以“优先级调整”为由结束了与Verve的合作，而这一决定也得到了Verve在其官方声明中的确认。尽管双方的合作原本计划持续四年，但实际上仅维持了两年。Verve在周四发布的一系列公告中，将这一消息以低调的方式处理，作为常规管线更新以及首席医疗官退休消息的补充说明。值得注意的是，Verve的主要候选药物VERVE-102正是一款针对肝脏的基因编辑疗法。VERVE-102通过单次注射靶向PCSK9基因，目的是降低低密度脂蛋白胆固醇（LDL-C）水平，用于治疗杂合子家族性高胆固醇血症（HeFH）。这种遗传性疾病会增加患者中风和心脏病发作的风险。目前，VERVE-102正在进行Ib期Heart-2临床试验。公司表示该药物耐受性良好，但尚未公布具体数据，预计相关结果将在2025年第二季度发布。VERVE-102成为Verve公司的核心产品，是因为另一款针对相同靶点的基因编辑药物VERVE-101在2024年4月的Ib期Heart-1研究中，因发现患者出现肝损伤迹象而被暂停。目前，尚未公开VERVE-101与VERVE-102之间的具体差异。尽管Verve与Vertex的合作告一段落，但这并未阻碍其与其他大型制药企业的合作。早在2023年，Eli Lilly就已支付6000万美元，获得了Verve的PCSK9项目相关权益。此次合作的终止，进一步凸显了基因治疗（或基因编辑）领域的高风险性和市场的不确定性。企业需要在技术创新与商业化落地能力之间寻求平衡。Verve能否凭借VERVE-102实现突破，以及其与Lilly合作的后续进展，将成为未来的关键观察点。与此同时，整个行业仍需解决定价、安全性及监管等系统性挑战，以推动基因疗法从实验室高效走向大众市场。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516422519","isCrawlerRequest":true}